P I Industries Ltd Q4 FY26 Earnings Call: Order Book Hits $1.1-1.2 Bn, Pharma Business Grows 40%

P I Industries Ltd held its Q4 FY26 earnings call on May 19, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Revenue, Margins & Balance Sheet

• FY26 revenue of Rs.67,137 Mn— Q4 FY26 contributed Rs.15,652 Mn; the full year delivered a three-year CAGR despite persistent industry headwinds (Segments 3, 4).
• FY26 EBITDA margin of 25%— in-line with guidance; gross margin for the year stood at 58% (Segments 3, 4, 7).
• Net cash balance of ~Rs.34 Bn (Rs.34,275 Mn)— trade working capital maintained at 139 days (Segments 3, 4).
• Effective tax rate of ~22% for FY26— management guided 23%–24% ETR for FY 2026-27 and thereafter (Segment 4).
• S&P Global Yearbook percentile improved to 98th— management cited "S&P Global Yearbook percentile improved to 98 percentile," placing PI among the top-rated chemical companies globally (Segment 3).
• Global agrochemical market in a multi-year down cycle— just-in-time purchasing, Middle East conflict disruption, and muted domestic demand due to elevated channel inventories and low crop prices (Segment 3).

Demand Pipeline & Revenue Trajectory

• Order book of $1.1–1.2 Bn as of the call— management declined a segment-wise breakdown, noting biologicals and pharma lack a typical order-book structure (Segment 12).
• Management expects positive revenue growth in FY 2026-27— driven by exports, global biologicals customer momentum, and domestic new brand launches (Segments 3, 4, 7).
• For FY 2026-27, worst-case scenario of "late stage single digit or early stage double digit" growth— management stated "growth for sure" but did not provide a specific number (Segment 14).
• New brands contributed ~18% of chemical exports in FY26— farmer platform revenue grew 40% in FY26; five new molecules commercialised in exports, four new products in domestic agri (Segment 4).
• New molecules contributed 18–20% of total portfolio in FY26— they grew faster than the overall business, though the macro environment slowed expected growth rates (Segment 6).
• Generics tilt in the near term— management observed the agrochemical market shifting toward generics, driven by stagnant commodity prices and rising farm input costs; innovation adoption has slowed cyclically but no structural change is expected (Segment 18).

Pharma, Biologicals & Electronic Chemicals

• Pharma business delivered 40% growth in FY26— driven by customer engagement and regulatory capabilities; management expects the next 2–3 years (FY 2026-27 to FY 2027-28) to focus on building capabilities, after which the business should enter an accelerated "J-curve" growth phase (Segments 3, 11).
• Pharma EBITDA expected when top line reaches Rs.500–600 Cr— management estimates this will take "a couple of years" from FY 2026-27 (implying FY 2028-29 or beyond); CDMO inquiries targeting Rs.500–600 Cr of business over the next 2–3 years (Segments 9, 14).
• US regulatory approval received for a novel foliar-applied biological nematode product— the third market after Brazil and Mexico; in Brazil, FY 2026-27 sales of this product are expected to "more than triple" (Segment 8).
• Global biology business targeting breakeven within the next couple of years (by ~FY 2027-28)— the segment has grown at a 20%+ CAGR over the past decade; FY 2026-27 R&D and launch costs will continue at Rs.50–200 Cr per year, with additional OPEX for a Rs.5,000 Cr product launch and global commercialisation (Segments 3, 11).
• Electronic chemicals: 4–5 molecules under evaluation— management targets "$100 million . . . over the next 4–5 years" (by ~FY 2030-31); an analyst cited a market estimate of $800 Mn over 5–6 years, but management did not confirm that figure (Segments 9, 16).
• Current pharma focus on capability building, not near-term profitability— a key challenge cited was a slowdown in biotech startup investments (external environment), though management noted the sector is now picking up (Segments 9, 17).

Cost Structure & Capital Deployment

• Gross margins at ~58–59% through FY 2025-26— management committed to maintaining the FY 2025-26 average gross margin level for FY 2026-27 but declined to give specific EBITDA margin guidance due to input-cost volatility (Segments 7, 16).
• EBITDA margins compressed to ~22% in recent quarters— down from 27–28% at the start of FY 2025-26; a 5% realisation decline in exports (period unspecified) and supply chain volatility were noted as headwinds (Segments 7, 10).
• FY 2025-26 CAPEX of Rs.1,100 Cr— pharma-specific CAPEX was Rs.91 Cr; management guided Rs.700–800 Cr CAPEX for FY 2026-27 to build manufacturing and R&D capabilities across pharma and agrochemicals (Segments 12, 14).
• Contract assets reduced from Rs.1,000 Cr (Dec '25) to Rs.700 Cr (Mar '26)— a 30–35% decline, but still above the Rs.400 Cr level at Mar '25; management expects to remain in the current range through FY 2026-27, noting that assets below Rs.600–700 Cr would be challenging to manage risk (Segments 6, 14, 16).
• Asset turns declined from 2.5x to 1.5x as of Q4 FY 2025-26— management explained that recent CAPEX targets multi-year ramp-ups which "typically require 4–5 years to reach maturity"; some capacity is expected to contribute in FY 2026-27 and the following 2–3 years (Segment 5).
• Capacity utilisation below 80% in FY26— indicative of slack despite new product additions; management prioritised volume growth to maintain market share (Segments 6, 10).
• Supply chain constraints impacting FY 2026-27 gross margins— management described it as "a difficult situation outside their control," acknowledging the risk of sudden changes (Segment 12).

NCE, NC Molecule & CSM Ramp

• First NCE (Axcelon), discovered in-house, expected to launch soon— management positioned this as marking PI's shift from contract manufacturer to global innovator; it is the first homegrown NCE in the domestic business (Segments 3, 4).
• NC molecule PI-son: regulatory applications planned by end of FY 2026-27 or FY 2027-28— management stated the molecule is "significant" but declined to quantify revenue potential relative to the current ~Rs.8,000 Cr scale; the first season of launch (likely FY27–FY28) will provide sizing (Segments 8, 15).
• Management emphasised that commercialising an innovation from discovery to market is a first for an Indian company— positioning the NC molecule as a benchmark for future pipeline development (Segment 15).
• CSM new product contribution: ~18–20% in FY 2025-26— up from ~15–18% in FY 2024-25, though absolute revenue from new products was roughly flat year-on-year due to the challenging global agricultural market (Segment 8).
• Five new molecules commercialised in chemical exports and four new products launched in domestic agri in FY26— included three herbicides and one insecticide; new brands contributed ~18% of chemical exports (Segment 4).
• Largest CSM molecule decline trajectory not disclosed— management declined to provide specific decline trajectory (gradual vs. cliff) for FY27–FY29, citing partnership confidentiality and competitive dynamics; analysts were advised to model genericisation patterns (Segment 15).

FY27 Guidance, Capability Build & Risks

• Positive revenue growth expected in FY 2026-27— ETR guided at 23%–24% for FY 2026-27 and thereafter; no specific EBITDA margin guidance was provided due to cost volatility (Segments 4, 7).
• Pharma: 2–3 years of capability building before J-curve acceleration— management expects FY 2026-27 to FY 2027-28 to lay the foundation; key investments include kilo labs commissioned during FY 2026-27, GMP facility upgrades, KSM materials, and biological offerings (Segments 11, 17).
• Management aims to become a fully integrated partner for pharma/biotech startups— combining strong manufacturing with regulated/unregulated environment capability; expects to be in a "unique competitive position" with best-in-class assets in the next couple of years (Segment 17).
• Electronic chemicals CAPEX of ~Rs.500 Cr gross block over FY27–FY29— directed toward multi-purpose and specialised assets targeting niche, complex chemistries; management expects asset turns to resemble early-stage CSM and scale over the next five years (by ~FY31) (Segments 10, 15).
• Rajnish Sarna stepped down from executive role— continues as non-executive director; group CFO Sanjay Agarwal will lead investor relations (Segment 3).
• Key external risks— supply chain constraints outside management's control, a multi-year down cycle in global agrochemicals, and a slowdown in biotech startup investments that is now recovering (Segments 3, 12, 17).
• Longer-term conviction unchanged— management believes innovation continues to deliver a steady CAGR over a longer horizon, and generics have likely bottomed; short-term trends reflect cyclical dynamics, not a structural shift (Segment 18).